Pub. Date : 2022 May
PMID : 35185356
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection. | remdesivir | ORF1a polyprotein;ORF1ab polyprotein | Severe acute respiratory syndrome coronavirus 2 |
| 2 | The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection. | remdesivir | ORF1a polyprotein;ORF1ab polyprotein | Severe acute respiratory syndrome coronavirus 2 |
| 3 | RdRp inhibitors, such as remdesivir (an anti-Ebola virus experimental drug) and favipiravir (an anti-influenza drug), inhibit RdRp and thus slow the progression of COVID-19 and associated clinical symptoms, as well as significantly shorten recovery time. | remdesivir | ORF1a polyprotein;ORF1ab polyprotein | Severe acute respiratory syndrome coronavirus 2 |
| 4 | RdRp inhibitors, such as remdesivir (an anti-Ebola virus experimental drug) and favipiravir (an anti-influenza drug), inhibit RdRp and thus slow the progression of COVID-19 and associated clinical symptoms, as well as significantly shorten recovery time. | remdesivir | ORF1a polyprotein;ORF1ab polyprotein | Severe acute respiratory syndrome coronavirus 2 |